trial · primary record
H3K27M-EIEs
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2030-06-30 |
| Primary endpoint | Percentage of adverse effects after H3K27M-EIE injection |
| Registry ID | NCT07501156 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:35.916Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07501156
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.